An FDA advisory panel voted 15-5 that Pfizer's Celebrex does not pose a greater risk of heart attacks and strokes than other analgesics, NPR reported Wednesday.
Doctors have been hesitant to prescribe the COX-2 inhibitor since Vioxx was pulled from the market in 2004 due to safety issues.
The FDA permitted Celebrex to remain on the market but directed Pfizer to conduct a large safety study.
Data from the study illustrated that Celebrex does not carry a larger risk of cardiovascular events than ibuprofen or naproxen.
Separately, the committee voted 12-7 in favour of adding a warning about the risk of using naproxen in patients currently on low-dose aspirin therapy.
Meanwhile, the panel voted 17-4 against adding a similar warning for patients taking ibuprofen and low-dose aspirin.
To read more NewsPoints articles, click here.